Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics

Blood (2024) 143 (13): 1242–1258.

https://doi.org/10.1182/blood.2023021581

Published: 2024

Includes: Supplemental data

Journal Articles

TP53 CRISPR/Cas9 Reveals Strict BAX Dependence in the Response to BH3 Mimetic Targeting MCL1

Romane Durand, Domitille Costes-Tertrais, Geraldine Descamps, Christelle Dousset, Sophie Maïga, Jean-Baptiste Alberge, Elise Douillard, Jennifer Derrien, Celine Bellanger, David Chiron, Stephane Minvielle, Cyrille Touzeau, Philippe Moreau, Martine Amiot, Patricia Gomez-Bougie, Agnes Moreau-Aubry, Catherine Pellat-Deceunynck

Blood (2022) 140 (Supplement 1): 4198–4199.

https://doi.org/10.1182/blood-2022-155862

Published: 2022

Journal Articles

Targeting Bcl-2 Proteins in Myeloma

Martine Amiot, PhD

Blood (2019) 134 (Supplement_1): SCI-11.

https://doi.org/10.1182/blood-2019-121103

Published: 2019

Journal Articles

Inhibition of ATR Overcomes Chemotherapy Resistance in p53 Deficient Myeloma Cells

Louise Bouard, MDin training, Benoit Tessoulin, MD PhD, Géraldine Descamps, PhD, Cyrille Touzeau, MD PhD, Philippe Moreau, MD, Martine Amiot, PhD, Catherine Pellat-Deceunynck, PhD

Blood (2019) 134 (Supplement_1): 3109.

https://doi.org/10.1182/blood-2019-122547

Published: 2019

Journal Articles

BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment

Patricia Gomez-Bougie, Sophie Maiga, Benoît Tessoulin, Jessie Bourcier, Antoine Bonnet, Manuel S. Rodriguez, Steven Le Gouill, Cyrille Touzeau, Philippe Moreau, Catherine Pellat-Deceunynck, Martine Amiot

Blood (2018) 132 (25): 2656–2669.

https://doi.org/10.1182/blood-2018-03-836718

Published: 2018

Includes: Supplemental data

Journal Articles

Respective Place of Venetoclax and MCL1 BH3 Mimetics in Multiple Myeloma Treatment

Patricia Gomez-Bougie, PhD, Sophie Maïga, Benoit Tessoulin, MD, Jessie Bourcier, MD, Antoine Bonnet, MD, Géraldine Descamps, PhD, Carolane Seiller, Cyrille Touzeau, MD PhD, Philippe Moreau, Catherine Pellat-Deceunynck, PhD, Martine Amiot, PhD

Blood (2018) 132 (Supplement 1): 953.

https://doi.org/10.1182/blood-2018-99-109987

Published: 2018

Journal Articles

CSF1R and BTK Inhibitions As Novel Strategies to Disrupt the Dialogue between Mantle Cell Lymphoma and Macrophages

Antonin Papin, Benoit Tessoulin, MD, Céline Bellanger, Anne Moreau, MD, Yannick LE Bris, MDPharmD, Herve Maisonneuve, MD, Philippe Moreau, Cyrille Touzeau, MD PhD, Martine Amiot, PhD, Catherine Pellat-Deceunynck, PhD, Steven Le Gouill, MD PhD, David Chiron, PhD

Blood (2018) 132 (Supplement 1): 2855.

https://doi.org/10.1182/blood-2018-99-114504

Published: 2018

Journal Articles

Human Myeloma Cell Lines Mutation Landscape: Toward a Rationale Use of Cell Lines to Assess Drug Efficacy Prediction in Myeloma

Benoit Tessoulin, MD, Agnes Moreau-Aubry, PhD, Alban Gaignard, PhD, Martine Amiot, PhD, Catherine Pellat-Deceunynck, PhD

Blood (2017) 130 (Supplement 1): 1770.

https://doi.org/10.1182/blood.V130.Suppl_1.1770.1770

Published: 2017

Journal Articles

The Use of a BH3 Mimetic Toolkit Reveals a Switch of Myeloma Patients Dependency from BCL2 at Diagnosis to MCL1 at Relapse

Antoine Bonnet, MD, Jessie Bourcier, MD, Patricia Gomez-Bougie, PhD, Sophie Maïga, Benoit Tessoulin, MD, Philippe Moreau, MDPhD, Steven Le Gouill, MDPhD, Catherine Pellat-Deceunynck, PhD, Cyrille Touzeau, MD PhD, Martine Amiot, PhD

Blood (2017) 130 (Supplement 1): 4383.

https://doi.org/10.1182/blood.V130.Suppl_1.4383.4383

Published: 2017

Journal Articles

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

Blood (2017) 130 (22): 2401–2409.

https://doi.org/10.1182/blood-2017-06-788786

Published: 2017

Includes: Supplemental data

Journal Articles

Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma

David Chiron, Céline Bellanger, Antonin Papin, Benoit Tessoulin, Christelle Dousset, Sophie Maiga, Anne Moreau, Julie Esbelin, Valérie Trichet, Selina Chen-Kiang, Philippe Moreau, Cyrille Touzeau, Steven Le Gouill, Martine Amiot, Catherine Pellat-Deceunynck

Blood (2016) 128 (24): 2808–2818.

https://doi.org/10.1182/blood-2016-06-720490

Published: 2016

Includes: Supplemental data

Journal Articles

The Oncolytic Measles Virus Preferentially Infects p53 Abnormal Myeloma Cells

Anne Lok, MD, Geraldine Descamps, PhD, Benoit Tessoulin, MD, Philippe Moreau, Steven Le Gouill, MD PhD, Frederic Tangy, PhD, Martine Amiot, Catherine Pellat-Deceunynck, PhD

Blood (2016) 128 (22): 310.

https://doi.org/10.1182/blood.V128.22.310.310

Published: 2016

Journal Articles

Lymphoid-like Environment, Which Promotes Proliferation and Induces Resistance to BH3-Mimetics, Is Counteracted By Obinutuzumab in MCL: Biological Rationale for the Oasis Clinical Trial

David Chiron, PhD, Celine Bellanger, Antonin Papin, Benoit Tessoulin, MD, Christelle Dousset, Sophie Maiga, Anne Moreau, MD, Julie Esbelin, MD, Valerie Trichet, PhD, Selina Chen-Kiang, PhD, Philippe Moreau, Cyrille Touzeau, MD, Steven Le Gouill, MD PhD, Martine Amiot, Catherine Pellat-Deceunynck, PhD

Blood (2016) 128 (22): 1096.

https://doi.org/10.1182/blood.V128.22.1096.1096

Published: 2016

Journal Articles

Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study

Shaji Kumar, MD, Ravi Vij, MD, Jonathan L. Kaufman, MD, Joseph Mikhael, MD, Thierry Facon, MD, Brigitte Pegourie, MD, Lofti Benboubker, Cristina Gasparetto, MD, Martine Amiot, Philippe Moreau, Stefanie Alzate, Jeremy Ross, Martin Dunbar, Tu Xu, Suresh Agarwal, Joel Leverson, Paulo Maciag, Maria Verdugo, Cyrille Touzeau

Blood (2016) 128 (22): 488.

https://doi.org/10.1182/blood.V128.22.488.488

Published: 2016

Journal Articles

Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results

Blood (2015) 126 (23): 4219.

https://doi.org/10.1182/blood.V126.23.4219.4219

Published: 2015

Journal Articles

Hypoxia-Inducible Factor (HIF)-1alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo

Paola Storti, PhD, Valentina Marchica, Denise Toscani, PhD, Irma Airoldi, PhD, Sophie Maiga, PhD, Marina Bolzoni, PhD, Nicoletta Campanini, Eugenia Martella, MD, Cristina Mancini, MD, Valentina Ferri, Gaetano Donofrio, PhD, Martine Amiot, PhD, Franco Aversa, MD, Nicola Giuliani, MD PhD

Blood (2015) 126 (23): 3012.

https://doi.org/10.1182/blood.V126.23.3012.3012

Published: 2015

Journal Articles

Biomarker and Ex Vivo Sensitivity Analysis of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Jeremy Ross, PhD, Martine Amiot, PhD, Brenda Chyla, PhD, Lisa Roberts-Rapp, Rasna Goswami, Sun Yan, Xin Huang, Anahita Bhathena, Sari Heitner Enschede, MD, Paulo Maciag, MD, Rod A. Humerickhouse, MD PhD, Evelyn McKeegan

Blood (2015) 126 (23): 2975.

https://doi.org/10.1182/blood.V126.23.2975.2975

Published: 2015

Journal Articles

BH3 Profiling Identifies Bcl-2 Dependency in Multiple Myeloma and Predicts Sensitivity to BH3 Mimetics

Cyrille Touzeau, MD, Jeremy Ryan, SM, Philippe Moreau, MD, Triona Ni Chonghaile, PhD, Steven Le Gouill, Paul G. Richardson, Kenneth C. Anderson, Martine Amiot, PhD, Anthony G. Letai, MD PhD

Blood (2014) 124 (21): 417.

https://doi.org/10.1182/blood.V124.21.417.417

Published: 2014

Journal Articles

PRIMA-1 Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

Benoît Tessoulin, Géraldine Descamps, Philippe Moreau, Sophie Maïga, Laurence Lodé, Catherine Godon, Séverine Marionneau-Lambot, Thibauld Oullier, Steven Le Gouill, Martine Amiot, Catherine Pellat-Deceunynck

Blood (2014) 124 (10): 1626–1636.

https://doi.org/10.1182/blood-2014-01-548800

Published: 2014

Journal Articles

Mantle-Cell Lymphoma (MCL) Cells Are Highly Sensitive To ABT-199 But Their Sensitivity May Be Altered By The Microenvironment Via The Up-Regulation Of Bcl-Xl and Bcl2A1

Cyrille Touzeau, MD, Carole Brosseau, PhD, Christelle Dousset, Catherine Pellat-Deceunynck, PhD, Steven Le Gouill, MD, PhD, Martine Amiot, PhD

Blood (2013) 122 (21): 4285.

https://doi.org/10.1182/blood.V122.21.4285.4285

Published: 2013

NARROW

A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics

TP53 CRISPR/Cas9 Reveals Strict BAX Dependence in the Response to BH3 Mimetic Targeting MCL1

Targeting Bcl-2 Proteins in Myeloma

Inhibition of ATR Overcomes Chemotherapy Resistance in p53 Deficient Myeloma Cells

BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment

Respective Place of Venetoclax and MCL1 BH3 Mimetics in Multiple Myeloma Treatment

CSF1R and BTK Inhibitions As Novel Strategies to Disrupt the Dialogue between Mantle Cell Lymphoma and Macrophages

Human Myeloma Cell Lines Mutation Landscape: Toward a Rationale Use of Cell Lines to Assess Drug Efficacy Prediction in Myeloma

The Use of a BH3 Mimetic Toolkit Reveals a Switch of Myeloma Patients Dependency from BCL2 at Diagnosis to MCL1 at Relapse

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma

The Oncolytic Measles Virus Preferentially Infects p53 Abnormal Myeloma Cells

Lymphoid-like Environment, Which Promotes Proliferation and Induces Resistance to BH3-Mimetics, Is Counteracted By Obinutuzumab in MCL: Biological Rationale for the Oasis Clinical Trial

Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study

Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results

Hypoxia-Inducible Factor (HIF)-1alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo

Biomarker and Ex Vivo Sensitivity Analysis of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

BH3 Profiling Identifies Bcl-2 Dependency in Multiple Myeloma and Predicts Sensitivity to BH3 Mimetics

PRIMA-1 Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

Mantle-Cell Lymphoma (MCL) Cells Are Highly Sensitive To ABT-199 But Their Sensitivity May Be Altered By The Microenvironment Via The Up-Regulation Of Bcl-Xl and Bcl2A1

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only